Emerging Company Profile
Atavistik: Identifying allosteric modulators of metabolic proteins
Emerging Company Profile: Utah spinout launching with $60M to identify allosteric regulatory sites on metabolic targets
TCG-built Atavistik Bio is launching with a $60M series A round to identify allosteric regulatory sites on disease-causing proteins.
Launching with a $60 million series A round, Atavistik is advancing an allosteric modulator discovery platform built on technology developed by Jared